News
AMTI
0.3780
+12.84%
0.0430
3 Analysts Have This to Say About Applied Molecular
Benzinga · 2d ago
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
Benzinga · 3d ago
Chardan Capital Downgrades Applied Molecular to Neutral
Benzinga · 3d ago
Applied Molecular Transport (AMTI) Gets a Hold from JMP Securities
TipRanks · 3d ago
--Chardan Downgrades Applied Molecular Transport to Neutral From Buy, Amid Uncertainty Regarding Clinical Programs and Company Strategy, Withdraws Price Target
--Chardan Downgrades Applied Molecular Transport to Neutral From Buy, Amid Uncertainty Regarding Clinical Programs and Company Strategy, Withdraws Price Target
MT Newswires · 3d ago
Applied Molecular To Explore Strategic Alternatives
NASDAQ · 3d ago
Applied Molecular Transport exploring strategic options; cutting 57% of staff
Seeking Alpha · 3d ago
BRIEF-Applied Molecular-On March 21, Approved Reduction Of Workforce By 35 Employees Across All Functional Areas, Resulting 26 Remaining Full-Time Employees
Reuters · 3d ago
BRIEF-Applied Molecular Transport Announces Corporate Leadership Change
Reuters · 3d ago
Applied Molecular Transport Tahir Mahmood Will Leave His Post As Chief Executive Officer; Shawn Cross, President And Chief Operating Officer, Will Now Serve As Chief Executive Officer And Has Been Appointed To The Board Where He Will Serve As Chair
Benzinga · 3d ago
Applied Molecular Transport Plans to Slash 57% Jobs While 'Exploring Strategic Alternatives'; CEO Tahir Mahmood to Step Down
Applied Molecular Transport Plans to Slash 57% Jobs While 'Exploring Strategic Alternatives'; CEO Tahir Mahmood to Step Down
MT Newswires · 3d ago
What Makes Applied Molecular Transport Inc. (AMTI) a New Buy Stock
NASDAQ · 03/14 16:00
Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Applied Molecular Transport (AMTI)
TipRanks · 03/10 05:30
Applied Molecular Transport GAAP EPS of -$0.58 beats by $0.01
Seeking Alpha · 03/09 22:56
BRIEF-Applied Molecular Transport Inc. - On March 7 Board Approved Reduction Of Co's Workforce By 16 Employees Across All Functional Areas Of Co
Reuters · 03/09 22:39
BRIEF-Applied Molecular Transport Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Corporate Update
Reuters · 03/09 21:57
Applied Molecular Q4 EPS $(0.58) Beats $(0.59) Estimate
Benzinga · 03/09 21:20
Expert Ratings for Applied Molecular
Benzinga · 03/06 15:00
Chardan Capital Reiterates Buy on Applied Molecular, Maintains $3 Price Target
Benzinga · 03/06 09:49
BRIEF-Applied Molecular Transport Presents Additional Data From Oral Amt-101 Phase 2 Fillmore Trial In Chronic Pouchitis
Reuters · 03/03 13:05
More
Webull provides a variety of real-time AMTI stock news. You can receive the latest news about Applied Molecular Transport Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AMTI
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company is building a portfolio of oral product candidates based on its technology platform, including AMT-101, an oral gastrointestinal (GI)-selective oral fusion of interleukin 10 (IL-10) that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The Company’s other product candidate, AMT-126, is a GI-selective oral fusion of interleukin 22 (IL-22). Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs.